Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)

NCT06239974

Status	RECRUITING
Phase	Not Applicable
Sponsor	The University of Hong Kong
Enrollment	94 participants

Key Eligibility Criteria

Inclusion (5)

- Stable recurrent chest pain.
- to 75 years old.
- Have coronary computed tomography (CT) angiogram or catheter coronary angiogram within 6 months showing non-obstructive coronary artery disease (\<50% coronary artery stenosis or fractional flow reserve \>0.8).
- Stress CMR MPR \<2.19 12 or Stress MBF \<2.19ml/g/min 13.
- Female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP),or is a WOCBP and agrees to follow contraceptive guidance during the study intervention period and for at least 1 month after the last dose of study intervention.

Exclusion (10)

- Systolic blood pressure \<100 mm Hg.
- Concurrent use of soluble guanylate cyclase stimulators (eg. Riociguat), or phosphodiesterase type 5 inhibitors (eg. vardenafil, tadalafil, and sildenafil).
- Has known allergy or sensitivity to any soluble guanylate cyclase stimulator.
- On long-acting nitrates (eg. isosorbide mononitrate)
- Known cardiomyopathy, complex congenital heart disease, endocarditis or pericarditis.

... and 5 more (see full listing online)

Locations (1 total)

The University of Hong Kong, Hong Kong, Hong Kong